aetherAI vs Proscia (2026)
Both sell a cleared image management and viewing platform, so the choice turns on what comes with it. aetherSlide is FDA cleared (K233126), approved in Taiwan and CE marked, and aetherAI adds its own AI for bone marrow smears and colonoscopy, approved in Taiwan and, for bone marrow, CE marked. Proscia's Concentriq AP-Dx is cleared (K230839, and K261380 in August 2026, which added cloud deployment and a change control plan), Health Canada licensed and CE marked under the IVDR; Proscia's own AI is research use only, and more than 230 applications from Proscia and other makers run on it.
- You want hematology or colonoscopy AI from the platform's own maker.
- Your hospitals are in Taiwan or Japan, where aetherAI names sites.
- You want viewing and AI from one vendor with approvals in Asia.
- You want many makers' applications and support for more than 45 scanners.
- Your security review asks for SOC 2 Type II, ISO 27001 and ISO 13485, which Proscia names.
- You want cloud deployment and a change control plan named in the clearance itself.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. aetherAI and Proscia are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | aetherAI | Proscia |
|---|---|---|
| Primary category | Digital Pathology AI | Digital Pathology AI |
| Founded | 2015 | 2014 |
| Headquarters | Taipei, Taiwan | Philadelphia, Pennsylvania, United States |
| Website | aetherai.com | proscia.com |
Side by Side
Select any grade to read the note behind it.
Product updates
The latest logged changes from each vendor, newest first, each linked to its source.
Proscia
-
Regulatory / FDA
Proscia received a new FDA 510(k) clearance for its Concentriq AP-Dx digital pathology platform.
Source
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Taipei based digital pathology and medical imaging AI company. Its aetherSlide image management and viewing system holds FDA clearance (K233126, 2024), Taiwan approval and CE marking, and is named at hospitals in Taiwan, Japan and Germany. It also sells aetherAI Hema, bone marrow smear analysis software approved in Taiwan and CE marked, and aetherAI Endo, computer aided polyp detection for colonoscopy approved in Taiwan, plus research applications for slide quality control, cell counting and IHC quantification.
Source: AI Health Index, September 2026
Digital pathology software company whose Concentriq platform manages, displays and analyzes whole slide pathology images for clinical laboratories and life sciences organizations. Its diagnostic edition, Concentriq AP-Dx, is FDA 510(k) cleared (K230839 in 2024 and K261380 in August 2026, which added cloud deployment and a change control plan), Health Canada licensed and CE marked under the EU IVDR for primary diagnosis on FFPE surgical pathology slides; the research editions are labeled Research Use Only, a distinction the company draws explicitly.
Source: AI Health Index, September 2026
Questions buyers ask
How do aetherAI and Proscia work with the EHR?
With Techman Robot and Hamamatsu Photonics it offers an automated arrangement in which a robot loads slides into a NanoZoomer scanner and images pass to aetherAI software.
With Proscia, the company states that AI recommended ancillary test requests flow back into the LIS rather than a separate ticket queue, which is a real workflow closure rather than a display feature. The platform also serves as a host environment for third party algorithms, with at least one external spatial biology vendor embedding its predictive biomarker technology into Concentriq. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
How do aetherAI and Proscia handle patient data?
In aetherAI's case, the only privacy policy covers visitors to the company website, defining the service as the website, and does not address slides, smears or colonoscopy video processed by the products. Nothing states whether aetherAI receives customer images for support or model development, what it retains, who de-identifies images, or how customers are told about model updates.
For Proscia, the platform page states that "everything in Concentriq stays within your organization, unless you give express permission to de-identify and share it to advance research", and that "your data is never used to train the models Concentriq runs". From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
What evidence is published for aetherAI and Proscia?
The corresponding author is at National Taiwan University Hospital, aetherAI employees are coauthors, and the paper describes the product as derived from the study rather than naming a version.
In Proscia's case, the earlier dermatopathology classifier was validated across two university hospitals and two commercial dermatopathology laboratories on more than 20,000 biopsy slides. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
How much do aetherAI and Proscia leave to the clinician?
For aetherAI Hema, which produces a bone marrow differential count, nothing published says who confirms the count, whether each classified cell is shown for review, what confidence level routes a smear to a manual count, or what happens to cells the software cannot classify.
With Proscia, the cleared clinical edition is an aid to the pathologist for viewing and interpreting images, and the company's AI applications are for research use only, so no model output reaches a diagnosis without a pathologist. The company's chief executive has publicly argued that the opportunity is removing administrative burden rather than diagnostic expertise, consistent with how the product is scoped. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Digital Pathology AI page.
Each FDA clearance covers the platform, not the AI. Neither publishes pricing. Rewritten 28 Sep 2026 after both records were reviewed.